Imunon Overview

  • Year Founded
  • 1982

Year Founded

  • Status
  • Public

  • Employees
  • 20

Employees

  • Stock Symbol
  • IMNN

Stock Symbol

  • Investments
  • 1

  • Share Price
  • $0.53
  • (As of Friday Closing)

Imunon General Information

Description

Imunon Inc is a clinical-stage biotechnology company focused on advancing a portfolio of treatments that harness the body's natural mechanisms to generate safe, effective and durable responses across a broad array of human diseases, constituting a differentiating approach from conventional therapies. It is developing its non-viral DNA technology across its modalities. The first modality, TheraPlas, is developed for the coding of proteins and cytokines in the treatment of solid tumors. The second modality, PlaCCine, is developed for the coding of viral antigens that can elicit an immunological response. The company's clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of ovarian cancer.

Contact Information

Website
www.imunon.com
Formerly Known As
Cheung Laboratories, Celsion
Ownership Status
Publicly Held
Financing Status
Corporation
Corporate Office
  • 997 Lenox Drive
  • Suite 100
  • Lawrenceville, NJ 08648
  • United States
+1 (609)
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Stock Exchange
NAS
Corporate Office
  • 997 Lenox Drive
  • Suite 100
  • Lawrenceville, NJ 08648
  • United States
+1 (609)

Imunon Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Imunon Stock Performance

As of 20-Nov-2026, Imunon’s stock price is $0.53. Its current market cap is $3.47M with 6.49M shares.

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$0.53 $0.56 $0.49 - $4.35 $3.47M 6.49M 150K -$3.31

Imunon Financials Summary

As of 30-Sep-2026, Imunon has a trailing 12-month revenue of null.

In Thousands,
USD
TTM 30-Sep-2026 FY 2025 31-Dec-2025 FY 2024 31-Dec-2024 FY 2023 31-Dec-2023
EV 8,220 7,549 4,730 (11,249)
Revenue 0 0 0 0
EBITDA (14,363) (13,796) (17,902) (20,604)
Net Income (15,036) (14,495) (18,620) (19,515)
Total Assets 12,009 12,288 9,717 21,918
Total Debt 6,937 1,009 1,139 1,625
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Imunon Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Imunon‘s full profile, request access.

Request a free trial

Imunon Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Imunon Inc is a clinical-stage biotechnology company focused on advancing a portfolio of treatments that harness the bod
Drug Discovery
Lawrenceville, NJ
20 As of 2026

Carlsbad, CA

Karmiel, Israel
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Imunon Competitors (46)

One of Imunon’s 46 competitors is Renova Therapeutics, a Venture Capital-Backed company based in Carlsbad, CA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Renova Therapeutics Venture Capital-Backed Carlsbad, CA
Protalix Biotherapeutics Formerly VC-backed Karmiel, Israel
Astellas Pharma Corporation Tokyo, Japan
Mustang Bio Formerly VC-backed Waltham, MA
Ayala Pharmaceuticals Corporation Wilmington, DE
You’re viewing 5 of 46 competitors. Get the full list »

Imunon Patents

Imunon Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
EP-4658324-A1 Process for producing dna formulations with lipopolymer delivery systems Pending 31-Jan-2023
US-20260216375-A1 Process for producing dna formulations with lipopolymer delivery systems Pending 31-Jan-2023
WO-2024163503-A1 Process for producing dna formulations with lipopolymer delivery systems Inactive 31-Jan-2023
EP-4587459-A1 Il-12 gene therapy and immune checkpoint inhibitor combination for treating cancer Pending 13-Sep-2022
EP-4587459-A4 Il-12 gene therapy and immune checkpoint inhibitor combination for treating cancer Pending 13-Sep-2022 A61K39/00
To view Imunon’s complete patent history, request access »

Imunon Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Imunon Acquisitions (1)

Imunon’s most recent deal was a Merger/Acquisition with EGEN (Pharmaceuticals) for . The deal was made on 20-Jun-2014.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
EGEN (Pharmaceuticals) 20-Jun-2014 Merger/Acquisition Drug Discovery
To view Imunon’s complete acquisitions history, request access »

Imunon ESG

Risk Overview

Risk Rating

Updated November, 04, 2026

41.72 | Severe Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

Management

Management is related to actions taken to manage ESG issues

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

of 13,593

Rank

Percentile

Pharmaceuticals

Industry

of 852

Rank

Percentile

Biotechnology

Subindustry

of 431

Rank

Percentile

To view Imunon’s complete esg history, request access »

Imunon FAQs

  • When was Imunon founded?

    Imunon was founded in 1982.

  • Where is Imunon headquartered?

    Imunon is headquartered in Lawrenceville, NJ.

  • What is the size of Imunon?

    Imunon has 20 total employees.

  • What industry is Imunon in?

    Imunon’s primary industry is Drug Discovery.

  • Is Imunon a private or public company?

    Imunon is a Public company.

  • What is Imunon’s stock symbol?

    The ticker symbol for Imunon is IMNN.

  • What is the current stock price of Imunon?

    As of 20-Nov-2026 the stock price of Imunon is $0.53.

  • What is the current market cap of Imunon?

    The current market capitalization of Imunon is $3.47M.

  • Who are Imunon’s competitors?

    Renova Therapeutics, Protalix Biotherapeutics, Astellas Pharma, Mustang Bio, and Ayala Pharmaceuticals are some of the 46 competitors of Imunon.

  • What is Imunon’s annual earnings per share (EPS)?

    Imunon’s EPS for 12 months was -$3.31.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process